SCHEMBL3370644

SCHEMBL3370644

N#Cc1c(Cl)cccc1Oc1ccccc1-c1cc[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.41
MAPT P10636 2/20 0.40
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
HSD11B1 P28845 1/20 0.38
EZH2 Q15910 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
MRGPRX4 Q96LA9 1/20 0.34
GAA P10253 2/20 0.34
ADRB2 P07550 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370649 0.81 TLR8 (0.57) TLR8MAPTADORA2AADORA1HSD11B1
SCHEMBL11508991 0.78 TLR8 (0.52) TLR8MAPTHSD11B1EZH2L3MBTL1
SCHEMBL3252001 0.73 IDO1 (0.55) MAPTL3MBTL1HPGDKMT2AGAA
SCHEMBL2628136 0.72 TLR8 (0.48) TLR8MAPTHSD11B1EZH2L3MBTL1
SCHEMBL2628135 0.71 MAPT (0.53) TLR8MAPTADORA2AADORA1HSD11B1
SCHEMBL9563030 0.70 IDO1 (0.56)
SCHEMBL14827159 0.69 TLR8 (0.46) TLR8MAPTHSD11B1EZH2L3MBTL1
SCHEMBL30926124 0.69 ESR2 (0.42) L3MBTL1GAA
SCHEMBL3401714 0.69 ESR2 (0.42) L3MBTL1GAA
SCHEMBL15394703 0.68 TLR8 (0.45) TLR8MAPTHSD11B1EZH2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266960-B1 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants EURO CELTIQUE SA (LU) 2014-01-22 EP disclosed
EP-2266960-A2 Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants EURO-CELTIQUE S.A. (LU) 2010-12-29 EP disclosed
EP-1173169-B1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO CELTIQUE SA (LU) 2010-05-12 EP disclosed
EP-1173169-A4 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO CELTIQUE SA (LU) 2007-04-04 EP disclosed
US-6737418-B2 CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS EURO-CELTIQUE S.A. (LU) 2004-05-18 US disclosed
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof EURO-CELTIQUE S.A. 2003-04-10 US disclosed
US-6414011-B1 CENTRAL NERVOUS SYSTEM DISORDERS EURO-CELTIQUE S.A. (LU) 2002-07-02 US disclosed
EP-1173169-A1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF Euro-Celtique S.A. (LU) 2002-01-23 EP disclosed
WO-2000057877-A1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069292-A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof GRIK5, GRIN3A, GRIK3 TLR8 2722/4885MAPT 454/4885ADORA2A 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.